Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
Abstract Peptide therapeutics are increasingly used in the treatment of disease, but their administration by injection reduces patient compliance and convenience, especially for chronic diseases. Thus, oral administration of a peptide therapeutic represents a significant advance in medicine, but is...
Guardado en:
Autores principales: | Sergei Pechenov, Jefferson Revell, Sarah Will, Jacqueline Naylor, Puneet Tyagi, Chandresh Patel, Lihuan Liang, Leo Tseng, Yue Huang, Anton I. Rosenbaum, Kemal Balic, Anish Konkar, Joseph Grimsby, J. Anand Subramony |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3ba0d823dad649b18d617f5537b9b8f7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Ben Jones, et al.
Publicado: (2018) -
Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee W Chia, et al.
Publicado: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010) -
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Mette Simone Aae Madsen, et al.
Publicado: (2019)